Join
Live feed
·
INSIDERFilingvia Quantisnow
Outlook Therapeutics Inc. logo

Chief Financial Officer Kenyon Lawrence A bought $28,446 worth of shares (5,000 units at $5.69), increasing direct ownership by 529% to 5,946 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
OTLK· Outlook Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OTLK (Outlook Therapeutics Inc.) and more on Quantisnow.